SAB Biotherapeutics, Inc.
SABS· Nasdaq
Released Aug 21, 2023, before the open
10-Q filed Aug 21, 2023, 52 days after period end · 0001437749-23-024224
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|
| Revenue | $85.52K | $6.35M | $18.21M |
| Net Income | -$6.88M | -$4.78M | -$2.94M |
| EPS Diluted | -$1.36 | -$0.11 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SAB Biotherapeutics, Inc. · CIK 1833214 · Engraved from SEC EDGAR